- Home
- INM vs CHEK Comparison
INM vs CHEK Comparison
Compare INM & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- CHEK
- Stock Information
- Founded
- INM 1981
- CHEK 2004
- Country
- INM Canada
- CHEK Israel
- Employees
- INM N/A
- CHEK N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- INM Health Care
- CHEK Health Care
- Exchange
- INM Nasdaq
- CHEK Nasdaq
- Market Cap
- INM 4.3M
- CHEK 3.9M
- IPO Year
- INM N/A
- CHEK 2015
- Fundamental
- Price
- INM $2.36
- CHEK $2.32
- Analyst Decision
- INM
- CHEK
- Analyst Count
- INM 0
- CHEK 0
- Target Price
- INM N/A
- CHEK N/A
- AVG Volume (30 Days)
- INM 47.0K
- CHEK 8.7M
- Earning Date
- INM 11-13-2025
- CHEK 11-14-2025
- Dividend Yield
- INM N/A
- CHEK N/A
- EPS Growth
- INM N/A
- CHEK N/A
- EPS
- INM N/A
- CHEK N/A
- Revenue
- INM $4,920,990.00
- CHEK N/A
- Revenue This Year
- INM N/A
- CHEK N/A
- Revenue Next Year
- INM N/A
- CHEK N/A
- P/E Ratio
- INM N/A
- CHEK N/A
- Revenue Growth
- INM N/A
- CHEK N/A
- 52 Week Low
- INM $1.72
- CHEK $0.56
- 52 Week High
- INM $8.27
- CHEK $3.13
- Technical
- Relative Strength Index (RSI)
- INM 56.86
- CHEK 84.28
- Support Level
- INM $2.11
- CHEK $0.65
- Resistance Level
- INM $2.28
- CHEK $3.13
- Average True Range (ATR)
- INM 0.11
- CHEK 0.23
- MACD
- INM 0.03
- CHEK 0.20
- Stochastic Oscillator
- INM 78.57
- CHEK 67.72
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.